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Deoxynucleotide sequencing of a cDNA for the dihydrolipoamide acetyltransferase (PDC-E,) component of human pyr- 
uvate dehydrogenase complex (PDC) revealed an open reading frame of 1848 base pairs corresponding to a leader sequen- 
ce of 54 amino acids and a mature protein of 561 amino acids (59551 Da). Both an amino-terminal lipoyl-bearing domain 
and a carboxy-terminal catalytic domain are present in the deduced amino acid sequence. The lipoyl-bearing domain 
contains two repeating units of 127 amino acids, each harboring one lipoic acid-binding lysine. Thus, mammalian PDC-E, 
differs as to the number of lipoic acid-binding sites from other dihydrolipoamide acyltransferases in both prokaryotic 
and eukaryotic organisms. 
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1. INTRODUCTION 
Dihydrolipoamide acetyltransferase (PDC-Ez, 
EC 2.3.1.12) is one of the six components of the 
mammalian pyruvate dehydrogenase complex 
(PDC) [1,2]. PDC-E2 is encoded by a nuclear gene 
and is synthesized as a precursor with a leader se- 
quence which is subsequently cleaved to generate 
the mature form in the mitochondria [3]. PDC-E2 
is made up of two heterologous domains: the car- 
boxyterminal inner core-forming (catalytic) do- 
main and the amino-terminal lipoyl-bearing 
domain, which are linked by a trypsin-sensitive 
hinge region [4]. Lipoic acid is covalently linked to 
a lysyl-residue of the lipoyl-bearing flexible do- 
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The nucleotide sequence presented here has been submitted to 
the EMBL/GenBank database under the accession no. YO0978 
main thereby allowing the functional group of the 
lipoyl-lysine to interact with active sites residing in 
other components of the complex. Here, we report 
the deduced amino acid sequence of human PDC- 
E2 including the core-forming and lipoyl-bearing 
domains. The deduced amino acid sequence 
establishes the presence of two lipoyl-binding sites 
in the lipoyl-bearing domain of human PDC-E2. 
An analysis of the structural relationship of human 
PDC-E2 as compared to the EZ components of 
other a-ketoacid dehydrogenase complexes is also 
presented. 
2. MATERIALS AND METHODS 
2.1. Sequencing strategy 
The isolation of seven h recombinant phage containing 
cDNAs for human PDC-E2 was previously reported [5]. These 
recombinants were digested with EcoRI or other restriction en- 
donucleases and the resultant cDNA fragments were cloned into 
M13mp19. Overlapping directional deletion clones were 
generated starting with single-stranded Ml3mp19 template, 
RD20 primer (New England Biolabs), and Tq DNA polymerase 
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Fig. 1. Partial restriction endonuclease map of PDC-E2 cDNA 
clones derived from hE2-1 and hE2-5 and their sequencing 
strategy. Arrows indicate the position and direction of deletion 
fragments that were sequenced. The solid box and the hatched 
box represent he coding region of the mature PDC-EZ and its 
leader sequence, respectively. 
[6]. Deoxynucleotide sequencing of overlapping single-stranded 
Ml3mpl9 clones was performed by the dideoxy chain- 
termination method [7] employing a modified T, DNA 
polymerase (Sequenase, US Biochemical). 
2.2. Northern analysis 
Total RNA from human heart and rat kidney was isolated 
and RNA blotting was performed as in [8], using a 1.4 kb 
EcoRl cDNA fragment of hEz-1 labeled with [(r-32P]dCTP by 
the random priming method [9]. 
3. RESULTS AND DISCUSSION 
A partial restriction endonuclease map of PDC- 
E2 cDNA (2583 bp) and the DNA sequencing 
strategy are shown in fig.1. The deoxynucleotide 
sequence and deduced primary amino acid se- 
quence from these clones are shown in fig.2. PDC- 
E2 cDNA contained an open reading frame of 1848 
base pairs which corresponded to a protein of 615 
amino acids. The identity of these two clones 
(XE2-1 and XEz-5) as PDC-E2 cDNA is established 
by the match of the deduced PDC-E2 amino acid 
Fig.2. Nucleotide sequence of PDC-E2 cDNA and its deduced 
amino acid sequence. Nucleotides are numbered 5’ to 3 ’ . 
Amino acid residues (one-letter code) of the mature form and 
its leader sequence are separately numbered with the mature 
peptide beginning at + 1. X indicates the stop codon. The two 
lipoyl-binding sites are underlined (solid line) and the lipoyl- 
binding lysine within each site is marked by an asterisk (*). The 
two repeating units in the lipoyl-binding domain are bracketed. 
The E, binding site (amino acid residues 272-303) is marked by 
a broken underline and a highly conserved stretch of amino 
acids near the carboxy-terminal is identified by a double broken 
underline. Several potential polyadenylation signals are 
overlined. 
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46 
Volume 240, number 1,2 FEBS LETTERS November 1988 
sequence with (i) a known sequence of 10 amino 
acids surrounding the lipoyl-binding lysine residue 
of bovine kidney PDC-EZ [lo], and (ii) 22 of 23 
residues of the amino acid sequence at the amino- 
terminal of bovine heart PDC-Ez. [The amino- 
terminal amino acid sequence (SLPPHEKVPL- 
PSLSPTMQAGTIA) generated from trypsin 
digestion of the lipoyl-bearing domain of bovine 
heart PDC-E2 (Thomas E. Roche, Kansas State 
University; personal communication).] The cal- 
culated molecular mass of the deduced amino acid 
sequence of the mature PDC-E2 (561 amino acids) 
is 59551 Da. The molecular mass of the leader se- 
quence of PDC-E2 is estimated to be approx. 
6000 Da. This is consistent with the previously 
reported mass based on mobility of the precursor 
PDC-E2 on SDS-PAGE [3]. 
The deduced amino acid sequence of human 
PDC-EZ shows the presence of the amino-terminal 
lipoyl-bearing domain and the carboxy-terminal 
catalytic domain, both of which have been 
demonstrated to be present in PDC-E2 based on 
the proteolytic cleavage of mammalian PDC-EZ [4] 
and the sequencing of E. cofi PDC-E2 [l I]. Our 
data show that human PDC-E2 contains two 
lipoyl-binding sites [amino acid residues 35-52 
(site I) and 162-179 (site II) in figs 2,3] in the 
lipoyl-bearing domain. The second lipoyl-binding 
site (site II) shows approx. 83% homology (15 out 
of 18 residues) with the first (site I) and the dif- 
ferences that exist between the two lipoyl-binding 
sites are conservative. The amino acid sequence of 
site II of human PDC-E2 is also identical to a 
lipoyl-binding site present in a deduced protein se- 
quence of rat liver PDC-E2 cDNA [12,13]. 
Fig.3. Comparison of the domain structures of E. coli and 
human liver PDC-Ez. The limits of these domains are 
approximate. K, the lipoyl-binding lysine; ( q ) lipoyl-bearing 
repeating units; (me) the highly conserved region surrounding 
the lipoyl-binding lysine residue; (0) Er-binding site; (a) 
catalytic domain; (M) the conserved region in the catalytic 
domain; and ( WI ) the alanine-proline rich region. 
Fig.4. Northern blot analysis of total RNA isolated from 
human heart (25 pg; lane 1) and rat kidney (50 fig; lane 2). The 
size of the different mRNA species was determined by 
comparing their electrophoretic mobility to that of ribosomal 
RNA. 
However, the deduced amino acid ‘sequence of 
PDC-E2 from rat Iiver did not extend far enough 
into the amino-terminus of the protein to include 
the lipoyl-binding site I. 
An earlier study suggested that there was only 
one functional lipoic acid-binding site per molecule 
of PDC-E2 based on radiolabeled acetylation of 
mammalian PDC [4]. Recently, Bradford et al. 
[14] were able to identify two different but closely 
related short peptides containing lipoyl-lysine 
residues. These investigators proposed that there 
are either two or more lipoyl-binding sites per 
mammalian PDC-E2 polypeptide or possible 
microheterogeneity of bovine PDC-E2 [14]. Our 
results (fig.2) demonstrate the presence of two 
lipoyl-binding sites per human PDC-E2 polypep- 
tide. This is in contrast to the Ez component of 
mammalian branched-chain a-ketoacid dehy- 
drogenase complex which contains only one lipoyl- 
binding site per polypeptide [13,15]. 
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Mammalian PDC-E2 differs from E. coli PDC- 
EZ in that the latter contains three repeating units 
of approx. 100 amino acids in its lipoyl-bearing do- 
main [lo]. Each repeating unit surrounds a lipoyl- 
binding lysine and a region rich in alanine and pro- 
line residues at the carboxy-terminal of each 
repeating unit [lo, 111. The repeating units in E. 
cofi PDC-E2 contain identical regions of 18 amino 
acids surrounding the critical lysine residue. The 
remaining amino acids in the repeating units show 
considerable homology (ranging from 69 to 80%), 
with many of the differences being conservative 
substitutions. In contrast, human PDC-E2 includes 
two similar repeating units of 127 amino acids each 
containing a conserved stretch of 38 amino acids 
(amino acid residues 35-72 and 162-199; 79% 
homology) encompassing the lipoyl-binding lysine 
residue (figs 2,3). 
A dihydrolipoamide dehydrogenase (E3) binding 
site has been identified based on sequence 
homology among the E2 components of the three 
cy-ketoacid dehydrogenase complexes [ 131. A se- 
quence of 32 amino acids (from residues 272 to 303 
in figs 2,3) which is highly homologous to the 
E3-binding site [ 131, is also present in human PDC- 
E2. Overall, there is approx. 90% homology in the 
E3-binding site between human and rat liver PDC- 
E2 [12] and 53% homology between human and E. 
coli PDC-E2 [l 11. Further comparison of the 
amino acid sequences of the catalytic domains of 
PDC-E2 from human liver and E. coli revealed [1 l] 
a segment of 14 amino acids (residues 530-543 in 
figs 2,3) near the carboxy-terminal with approx. 
79% homology: 
Human liver PDC-E2: . ..LS CDHRVVDGAVGA... 
E. co/i PDC-Ez: . ..L S F DHRVI DGADGA . . . 
Although the nucleotide sequence encoding this 
region in rat liver PDC-E2 cDNA [12] is largely 
preserved, the deduced amino acid sequence of this 
segment of rat liver PDC-E2 is apparently altered 
due to a shift in its reading frame. A histidine 
residue is conserved in both sequences and this 
amino acid may serve as the active site residue for 
catalysis. 
Northern blot analysis of RNA isolated from 
human heart and rat kidney showed the presence 
of three hybridizing species (fig.4). This could be 
either due to the presence of multiple polyadenyla- 
tion signals in the 3 ’ untranslated region of PDC- 
Ez, alternative splicing sites, or multiple transcrip- 
tion initiation sites. 
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